RxDoctor Payments Data

Charles Weber, MD

Rheumatology · Wall Township, NJNPI 1144213042

Payments from drug & device makers

$518in general payments, 2019–2025

Across 32 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$117
  • AbbVie$114
  • Amgen$95
  • Novartis$57
  • Aurinia Pharma U.S., Inc.$43
  • Genentech USA, Inc.$36
  • plus $56 from 3 others

What the payments were for

  • Food & beverage$46189%
  • Education$5711%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer7$117
AbbVie7$114
Amgen(2 entities)6$95
Novartis4$57
Aurinia Pharma U.S., Inc.1$43
Genentech USA, Inc.3$36
Sanofi2$31
Organon1$13
Boehringer Ingelheim1$12

How this compares

$518 in reported general payments places this provider in the 25th percentile of 234 rheumatology providers in New Jersey.

See all rheumatology providers in New Jersey

Medicare billing

Part B allowed, 2024
$140,917
Medicare patients
208
Services billed
1,459

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept32$245,654
OtezlaApremilast43$204,370
Xeljanz XrTofacitinib Citrate31$177,237
TremfyaGuselkumab12$162,023
BenlystaBelimumab19$123,148
Cosentyx Sensoready (2 Pens)Secukinumab17$120,750
OrenciaAbatacept13$72,035
XeljanzTofacitinib Citrate11$61,308
Cimzia (2 Pack)Certolizumab Pegol11$60,621
Teriparatide16$53,021
ProliaDenosumab24$40,631
AmbienZolpidem Tartrate37$30,860
Diclofenac Sodium36$22,693
XanaxAlprazolam23$17,327
SavellaMilnacipran Hcl12$13,337

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla, Prolia$95$245,00167 claims
PfizerXeljanz, Eliquis$117$71,99028 claims
AbbVieSavella$114$13,33712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 234 rheumatology providers in New Jersey.

Other rheumatology in Wall Township

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →